September 20, 2019 | Coralville, IA.
Viewpoint Molecular Targeting, Inc. was awarded a Phase II Small Business Innovation Research (SBIR) grant valued at $2 million from the National Cancer Institute (NCI). This award will support preclinical development and a phase 1 clinical imaging trial of a Viewpoint product in metastatic melanoma patients. The phase 1 clinical imaging trial will take place at Mayo Clinic in Rochester, MN and is an insightful key step of product development in advance of companion therapeutic trials.
“This award is an excellent next step in advancing Viewpoint’s new therapy to the clinical stage. We could not be more excited about our progress and to expand our clinical trial sites.”–MICHAEL SCHULTZ, Viewpoint Co-Founder and Chief Science Officer